Corbus Pharmaceuticals Holdings, Inc.

Listed Company

CRBPCIK 0001595097NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-78.54M

Total Assets

$168.19M

Equity

$147.50M

Shares Out

18.53M

Op. Cash Flow

$-64.49M

CRBP$9.07+7.09% · past yearDBEQ Basic

Daily closing prices

Business

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies in oncology and obesity. Its pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 for solid tumors, and CRB-913, a peripherally restricted CB1 receptor inverse agonist for obesity treatment, currently advancing through Phase 1/2 and Phase 1b clinical trials respectively. The company operates through licensed intellectual property agreements with third-party manufacturers supplying drug candidates for pre-clinical and clinical development. CRB-701 has received fast track designation from the FDA for cervical cancer and head and neck squamous cell carcinoma.

Summary from 10-K filed 2026-03-09

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	70	32	31	16	36
General and administrative	15	16	14	19	20
Total operating expenses	85	49	45	40	57
Operating loss	−85	−49	−45	−40	−56
Interest and investment income, net	6	6	2	—	—
Interest expense	0	−2	−4	—	—
Other income, net	1	4	3	−48,773	12
Total other income, net	7	9	474,000	−3	10
Net loss	−79	−40	−45	−42	−46
Net loss per share, basic	−5.9	−3.68	−10.31	−10.15	−11.15
Net loss per share of common stock diluted	−5.9	−3.68	−10.31	−10.15	−11.15
Weighted average number of common shares outstanding, basic	13	11	4	4	4
Weighted average number of common shares outstanding, diluted	13	11	4	4	4
Net Income (Loss)	−79	−40	−45	−42	−46
Change in unrealized (loss) gain on marketable debt securities	−88,000	36,000	125,000	−63,647	−62,445
Total other comprehensive (loss) income	−88,000	36,000	125,000	−63,647	−62,445
Total comprehensive loss	−79	−40	−44	−42	−46

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	28	17	14	17	25
Investments	135	132	7	42	73
Restricted cash	670,000	285,000	192,000	192,475	192,475
Prepaid expenses and other current assets	3	4	2	791,616	2
Total current assets	167	153	24	60	100
Restricted cash	0	385,000	478,000	477,425	477,425
Property and equipment, net	159,000	385,000	973,000	2	2
Operating lease right-of-use assets	1	2	3	4	5
Total assets	168	156	28	66	108
Accounts payable	2	5	3	2	2
Accrued expenses	17	5	11	6	10
Operating lease liabilities, current	2	2	1	1	1
Total current liabilities	21	12	32	13	17
Operating lease liabilities, noncurrent	0	2	3	5	6
Total liabilities	21	13	35	33	39
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and December 31, 2024	0	0	0	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized,17,611,511 and 12,179,482 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	2,000	1,000	0	417	416
Additional paid-in capital	703	619	430	425	419
Accumulated deficit	−555	−477	−437	−392	−350
Accumulated other comprehensive loss	−53,000	35,000	−1,000	−126,092	−62,445
Total stockholders equity	148	142	−7	33	69
Total liabilities and stockholders equity	168	156	28	66	108

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	6	6	3	6	9
Depreciation expense	233,000	588,000	641,000	762,995	999,817
Net amortization of premiums and discounts on investments	−1	−3	−506,000	124,875	—
Amortization of debt discount	0	396,000	824,000	742,478	700,613
Other	−229,000	189,000	−19,000	—	—
Decrease (increase) in prepaid expenses and other current assets	634,000	−1	−1	—	—
Decrease in other assets	0	212,000	−57,000	—	—
Decrease in operating lease right-of-use asset	1	930,000	—	—	—
Decrease in other long-term liabilities	0	−44,000	22,000	—	—
(Decrease) increase in accounts payable	−2	2	1	−256,835	−6
Increase (decrease) in accrued expenses	11	−6	5	−4	−12
Decrease in operating lease liabilities	−2	−1	−1	−1	−1
Net cash used in operating activities	−64	−42	−36	−38	−48
Purchases of property and equipment	−7,000	0	0	−13,449	−54,172
Purchases of investments	−163	−181	−34	−86	−87
Proceeds from sales and maturities of investments	161	59	70	116	14
Net cash used in investing activities	−2	−121	36	30	−73
Proceeds from issuance of common stock and pre-funded warrants, net	77	182	53,000	—	63
Repayment of short-term borrowings	0	−301,000	−426,000	−866,865	−926,595
Repayment of long-term borrowings	0	−15	−3	−2	—
Net cash provided by (used in) financing activities	77	167	−3	−533,615	61
Net increase in cash, cash equivalents, and restricted cash	11	3	−3	−8	−61
Cash paid during the period for interest	0	3	3	2	2
Write-off of fully depreciated property and equipment	0	71,000	178,000	0	544,752
Common stock issuance costs not yet paid	62,000	75,000	0	—	—
Issuance of common stock for conversion of convertible debt	0	1	875,000	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Corbus Pharmaceuticals Holdings, Inc.'s CIK number?

Corbus Pharmaceuticals Holdings, Inc.'s SEC CIK number is 0001595097 (1595097). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Corbus Pharmaceuticals Holdings, Inc.'s SEC filings?

All of Corbus Pharmaceuticals Holdings, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Corbus Pharmaceuticals Holdings, Inc. last report earnings?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-218250). This is Corbus Pharmaceuticals Holdings, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Corbus Pharmaceuticals Holdings, Inc.'s most recent earnings 8-K?

Corbus Pharmaceuticals Holdings, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-218250. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Corbus Pharmaceuticals Holdings, Inc.'s latest earnings 8-K →
Look up any company's CIK number →